The regulator's reliance on double-blind, placebo-controlled trials with exhaustive inclusion and exclusion criteria is incompatible with today's precision medicine.
If we don't clean up our act and do something about predatory pricing scandals, we'll wind up with Washington bureaucrats telling us what we can charge for our products.
If we were going to be one of a kind, we needed a staff that understood and had lived through what our clients were facing.
Apparently, Dr. Ezekiel Emanuel loves to open his window and shout "fire!"
That 700% price hike created an issue that threatens years of pharma progress
Before you fire up your outrage and vent your spleen, take a long look inside your parents' (or your own) medicine chest
In Jack Welch's view, one of the worst mistakes a manager can make is . . .
Click here to learn about the Agency Issue.
- When it comes to professional ads, print makes its comeback
- Amgen takes issue with yet-to-be published multiple-myeloma drug report
- How Watson for Oncology is advancing cancer care
- Creative partners should push pharma clients to tell better stories
- Retaining talent: How pharma can compete with Google